Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes: [Letter]

Abstract

To the Editor: In the trials of the Canagliflozin Cardiovascular Assessment Study (CANVAS) Program (Aug. 17 issue),1 patients who had been assigned to receive canagliflozin had significantly lower rates of the primary outcome (a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke) than those assigned to receive placebo (hazard ratio, 0.86; 95% confidence interval [CI], 0.75 to 0.97).